Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EBITDA (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed EBITDA for 7 consecutive years, with -$23.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 52.99% to -$23.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$149.7 million, a 28.83% increase, with the full-year FY2025 number at -$149.7 million, up 28.83% from a year prior.
  • EBITDA was -$23.6 million for Q4 2025 at Pliant Therapeutics, up from -$26.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$22.8 million in Q1 2021 to a low of -$56.3 million in Q1 2025.
  • A 5-year average of -$37.1 million and a median of -$35.7 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 305.99% in 2021, then soared 53.34% in 2025.
  • Pliant Therapeutics' EBITDA stood at -$24.7 million in 2021, then plummeted by 39.98% to -$34.6 million in 2022, then fell by 12.42% to -$38.9 million in 2023, then decreased by 29.34% to -$50.3 million in 2024, then soared by 52.99% to -$23.6 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's EBITDA are -$23.6 million (Q4 2025), -$26.3 million (Q3 2025), and -$43.5 million (Q2 2025).